The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback